Since ICAM-1 expression is upregulated when SCLC cells acquire resistance to etoposide (Figure 5a and b, and Supplementary Figure 6), patients with HER2-positive and etoposide-resistant SCLC are ideal candidates for trastuzumab-based therapy. The gene discussed is ERBB2; the disease is small cell lung carcinoma.